Dobrin Nedelkov (Presenter)
Biodesign Institute, Arizona State University
Bio: Before coming to ASU in 2013, Dr. Nedelkov spent 14 years at Intrinsic Bioprobes leading research and development in the field of proteomics and protein biomarkers. Prior to joining Intrinsic Bioprobes in 1999, Dr. Nedelkov was Postdoctoral Associate at Yale University, in the Department of Molecular Biophysics and Biochemistry. Dr. Nedelkov received his Ph.D. in Chemistry and Biochemistry from Arizona State University in 1997. Dr. Nedelkov has authored over 90 peer reviewed scientific articles, edited a book on New and Emerging Proteomics Techniques, presented at over 60 scientific meetings, and has 4 issued patents and several pending patent applications.
Authorship: Dobrin Nedelkov
Biodesign Institute, Arizona State University
Short Abstract The last decade has seen increased efforts to bring MS-based protein tests into clinical labs; however, only a dozen such tests have been adopted thus far. Even when MS approaches result in new protein biomarkers discovery, enzymatic immunoassays oftentimes replace MS in clinical lab tests. One way to drive translation and adoption of MS protein tests is to target protein features that could only be detected with MS - such as post-translational modifications (PTMs) – thus generating both content and demand. Discussed in this presentation will be some viable PTM protein targets and the path forward for these clinical MS protein tests. |
Long Abstract
The last decade has seen increased efforts to bring MS-based protein tests into clinical labs; however, only a dozen such tests have been adopted thus far. Even when MS approaches result in new protein biomarkers discovery, enzymatic immunoassays oftentimes replace MS in clinical lab tests. One way to drive translation and adoption of MS protein tests is to target protein features that could only be detected with MS - such as post-translational modifications (PTMs) – thus generating both content and demand. Discussed in this presentation will be some viable PTM protein targets and the path forward for these clinical MS protein tests.
References & Acknowledgements:
Description | Y/N | Source |
Grants | no | |
Salary | no | |
Board Member | no | |
Stock | no | |
Expenses | no |
IP Royalty: no
Planning to mention or discuss specific products or technology of the company(ies) listed above: | no |